Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rodriguez-Ables, Lilia
NCT06267560: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD	Recruiting	3	400	US	TQJ230, pelacarsen, Placebo	Novartis Pharmaceuticals	Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease	03/27	03/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain	Recruiting	2	384	US	RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo	Reata, a wholly owned subsidiary of Biogen	Diabetic Peripheral Neuropathic Pain	08/26	08/26
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.	Terminated	N/A	715	Europe, Japan, US, RoW	THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence	Philip Morris Products S.A.	COPD, Smoking, Tobacco Use	09/24	09/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rodriguez-Ables, Lilia
NCT06267560: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD	Recruiting	3	400	US	TQJ230, pelacarsen, Placebo	Novartis Pharmaceuticals	Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease	03/27	03/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain	Recruiting	2	384	US	RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo	Reata, a wholly owned subsidiary of Biogen	Diabetic Peripheral Neuropathic Pain	08/26	08/26
NCT05569005: Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.	Terminated	N/A	715	Europe, Japan, US, RoW	THS use, Tobacco Heating System 3.0, Cigarette, Smoking Abstinence	Philip Morris Products S.A.	COPD, Smoking, Tobacco Use	09/24	09/24